Withdrawal of the Marketing Authorisation Application of COVID-19 Vaccine Candidate Skycovion
SK Chemicals GmbH withdrew its application for a marketing authorisation of the recombinant protein-based vaccine candidate Skycovion for the prevention of COVID-19 on 1 September 2023. The marketing authorisation application had been under review by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) since August 2022. The CHMP informed that the company had not provided enough data to support the application. The company stated that its withdrawal was based on commercial reasons.